Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ALDX 
Aldeyra The (ALDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: ALDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -53.56% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 189.87M USD | Price to earnings Ratio - | 1Y Target Price 8.67 |
Price to earnings Ratio - | 1Y Target Price 8.67 | ||
Volume (30-day avg) 915345 | Beta 0.68 | 52 Weeks Range 1.14 - 7.20 | Updated Date 06/20/2025 |
52 Weeks Range 1.14 - 7.20 | Updated Date 06/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.6% | Return on Equity (TTM) -65.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 115377576 | Price to Sales(TTM) - |
Enterprise Value 115377576 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.5 | Shares Outstanding 59895600 | Shares Floating 47667904 |
Shares Outstanding 59895600 | Shares Floating 47667904 | ||
Percent Insiders 3.13 | Percent Institutions 56.16 |
Analyst Ratings
Rating 4.71 | Target Price 8.29 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aldeyra The
Company Overview
History and Background
Aldeyra Therapeutics, Inc. (ALDX) is a biotechnology company focused on developing and commercializing innovative therapies for immune-mediated diseases. Founded in 2004, it has focused on novel approaches to treat diseases through its reactive aldehyde species (RAS) platform.
Core Business Areas
- Ophthalmology: Development of therapies for ocular inflammation and dry eye disease.
- Systemic Immunometabolic Diseases: Research and development of treatments for systemic diseases driven by immune dysfunction.
Leadership and Structure
Todd C. Brady, MD, PhD is the President and CEO. The company has a standard organizational structure with various departments dedicated to R&D, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Reproxalap (Dry Eye Disease): Reproxalap is Aldeyra's lead product candidate for treating dry eye disease. It has completed phase 3 clinical trials. Competitors include AbbVie (AGN) with Xiidra, Novartis (NOVN) with Cyclosporine, and Sun Pharma (SUNPH) with Cequa.
- ADX-2191 (Proliferative Vitreoretinopathy): ADX-2191 is an investigational drug for proliferative vitreoretinopathy (PVR), a rare and serious eye disease. Market share data is unavailable as the product is not yet approved. No other drug exists for this specific indication.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive, with a focus on innovation and regulatory approvals. The market for ophthalmology drugs is growing due to aging populations and increased screen time.
Positioning
Aldeyra is a clinical-stage company focusing on niche markets with unmet medical needs. Its competitive advantage lies in its RAS platform and targeted therapies.
Total Addressable Market (TAM)
The Dry Eye Disease Market alone is expected to reach several billion USD. Aldeyra is aiming to capture a significant portion of this market with reproxalap.
Upturn SWOT Analysis
Strengths
- Novel RAS platform
- Promising clinical trial results for reproxalap
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Reliance on successful clinical trial outcomes
- No currently marketed products
- Limited financial resources compared to larger pharmaceutical companies
- Regulatory approval risk
Opportunities
- Potential FDA approval of reproxalap
- Expansion of RAS platform to other indications
- Partnerships with larger pharmaceutical companies
- Growing market for dry eye disease therapies
Threats
- Failure to obtain regulatory approval
- Competition from established pharmaceutical companies
- Patent challenges
- Adverse events in clinical trials
Competitors and Market Share
Key Competitors
- ABBV
- NOVN
- SUNPH
Competitive Landscape
Aldeyra is a smaller player compared to established pharmaceutical companies. Its advantage lies in its novel mechanism of action and focus on specific unmet needs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on clinical trial successes and regulatory approvals. Historical growth is limited due to pre-revenue status.
Future Projections: Future growth is tied to the potential commercialization of reproxalap and other pipeline products. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Focusing on completing clinical trials, preparing for potential commercial launch of reproxalap.
Summary
Aldeyra Therapeutics is a clinical-stage biopharmaceutical company with a focus on immune-mediated diseases. Its lead product candidate, reproxalap, shows promise in treating dry eye disease, but success hinges on regulatory approval. The company faces challenges due to its limited financial resources and competition from larger pharmaceutical companies. The potential approval of reproxalap could significantly boost its growth, while clinical trial failures and competition remain key risks. Aldeyra is still a relatively small player, and therefore the risk factor is higher compared to competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Aldeyra Therapeutics Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aldeyra The
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2014-05-02 | CEO, President & Director Dr. Todd C. Brady M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.aldeyra.com |
Full time employees 8 | Website https://www.aldeyra.com | ||
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.